Sign in

You're signed outSign in or to get full access.

Chelsey Berstler

Executive Vice President, Personal Care Services at MODV
Executive

About Chelsey Berstler

Chelsey Berstler is Executive Vice President, Personal Care Services (PCS) at ModivCare, appointed June 10, 2024, age 45; she holds an Executive Education certificate from Stanford GSB and a bachelor’s from Bethel University . She previously served as Chief Commercial Officer at NationsBenefits (Jun 2023–Jun 2024) and spent ~20 years at UnitedHealth Group/Optum in senior leadership roles . Company performance context relevant to her incentive design: 2024 Compensation Adjusted EBITDA was approximately $123 million, resulting in a 0% payout under the 2024 STI; PRSUs introduced in 2024 are tied 40% to EBITDA goals and 60% to relative TSR, aligning compensation with value creation .

Past Roles

OrganizationRoleYearsStrategic Impact
NationsBenefitsChief Commercial OfficerJun 2023–Jun 2024Led significant portions of workforce across call center, client services, operations; drove market strategy, performance, sales and marketing .
UnitedHealth Group (UnitedHealthcare, Optum)VP Medicare Operations Performance; VP Supply Chain & Payment Integrity; VP Affordability; Chief of Staff (OptumRx & Global)~2003–2023 (two-decade tenure)Senior leadership across operations, affordability, payment integrity; executive staff roles supporting large-scale business lines .

External Roles

OrganizationRoleYears
The Redemption ProjectBoard MemberNot disclosed

Fixed Compensation

YearBase Salary (Annual)Target Bonus %Actual Bonus PaidNotes
2024$425,000 90% of salary $0 (STI paid at 0% due to Compensation Adjusted EBITDA outcome) Salary actually paid in 2024 was $286,576 (includes consulting payments prior to appointment) .
2024 Sign-on$150,000 (after taxes/deductions) Paid after one year of employment, or if terminated by the company for any reason other than for cause within one year .

Performance Compensation

Short-Term Incentive (STI)

ComponentMetric/WeightingTargetActual/PayoutDesign Notes
Company PerformanceCompensation Adjusted EBITDA (75%) Board-approved 2024 budget linkage ~$123M achieved; payout 0% of target Payout formula driven entirely by Comp Adj EBITDA; 2024 paid 0% .
Individual GoalsIndividual performance (25%) Committee-approved objectives 0% overall STI (company-level drove zero payout) Same structure as prior years; design emphasizes consolidated performance .
Chelsey’s STI Target90% of salary $382,500 (annualized) $0 (2024 STI) Annualized targets do not equal amounts paid due to partial-year and zero payout .

Long-Term Incentives (LTI) – 2024 Grant

Grant DateInstrumentShares GrantedGrant Date Fair ValueMix & VestingPerformance Metrics
7/31/2024RSUs6,518 Part of $336,127 total RSUs vest in three approximately equal installments on the first, second, and third anniversaries of grant date (expected: 7/31/2025, 7/31/2026, 7/31/2027), subject to continued employment .Time-based retention; dividends accrue but pay only upon vest, no voting rights .
7/31/2024PRSUs9,777 Part of $336,127 total PRSUs vest on the third anniversary of grant date (expected: 7/31/2027) subject to continued employment and performance .40% tied to EBITDA goals; 60% tied to Relative TSR (rTSR) versus peers; introduced in 2024 to align pay-for-performance .
2024 LTI MixPRSUs 60% / RSUs 40%Structure intended to motivate long-term retention and performance alignment .

The RSUs/PRSUs granted in 2024 represent inducement awards; Chelsey had no stock option awards in 2024 .

Equity Ownership & Alignment

ItemDetail
Beneficial Ownership (Record Date)No shares beneficially owned; percent of class less than 1% (*) .
Outstanding Unvested RSUs (12/31/2024)6,518 RSUs; market value $77,173 (at $11.84/share) .
Outstanding PRSUs (Target vs. Threshold presentation at 12/31/2024)Target PRSUs granted: 9,777 ; Outstanding table presents threshold count 4,889 with market/payout value $47,766 (presentation at 50% threshold) .
Stock Ownership GuidelinesOther NEOs required to hold shares equal to 3x annual base salary; continuing NEOs must hold compensatory shares until guideline met .
Compliance Status (12/31/2024)None of the NEOs met required holding level at year-end .
Hedging/PledgingAnti-hedging and anti-pledging policies prohibit such transactions or pledging of Company stock for executives and directors .
OptionsNo options outstanding for Chelsey; company disclosure shows RSUs/PRSUs only for her .

Employment Terms

TriggerCash PaymentEquity AccelerationHealth CoverageTotal (excl. LTD)Notes
Resignation for Good Reason$425,000 $77,173 (RSUs/PRSUs per terms) $44,366 (up to 12 months) $546,539 Good Reason includes material base pay reduction, >50-mile relocation, or material reduction in responsibilities; notice/cure process applies .
Termination without Cause$425,000 $44,366 (up to 12 months) $469,366 Pro rata STI eligible per offer (with Ms. Berstler’s terms) .
Termination Upon Change in Control$212,500 (six months base) $77,173 $22,183 (six months) $311,856 Double-trigger applies: payment/acceleration only upon termination in connection with/within 12 months after a Change in Control; PRSUs from 2023 have special treatment; RSUs/options accelerate for certain termination scenarios .
Disability$10,000 monthly LTD until age 65 (policy) LTD benefit policy applies to all NEOs under age 60 .
Death$100,000 life insurance proceeds $100,000 Company-paid life insurance for NEOs .
ClawbackCompany clawback allows recovery of cash/equity incentive compensation for restatements within prior 3 fiscal years per Nasdaq Rule 10D-1; additional clawbacks may be imposed in award agreements .

Double-trigger framework governs change-in-control benefits; no excise tax “gross-ups” and no single-trigger acceleration per Company “what we do not do” policies .

Compensation Structure Observations

  • Equity-heavy mix: Inducement LTI split 60% PRSUs/40% RSUs; PRSU design emphasizes EBITDA and rTSR performance alignment .
  • STI rigor: Consolidated Comp Adjusted EBITDA drove 0% payout in 2024, evidencing pay-for-performance mechanics .
  • Limited perquisites: All other compensation of $8,062 in 2024; Company limits executive perquisites and maintains clawback, ownership guidelines, anti-hedging/pledging .

Equity Vesting Timeline (Expected, subject to continued employment and PRSU performance)

  • RSUs: 7/31/2025, 7/31/2026, 7/31/2027 (three equal tranches) .
  • PRSUs: 7/31/2027 (performance-based vesting at 3-year cliff) with 40% EBITDA and 60% rTSR conditions .

Performance & Track Record Context

  • PCS operating model: PCS transitioned from a decentralized model to a centralized hybrid operating model in 2024 to balance efficiency with local market expertise, contemporaneous with Ms. Berstler’s onboarding; ModivCare highlighted retention of core leadership and her addition .
  • Company outcomes: 2024 revenue maintained consistent with 2023 despite Medicaid redetermination and reimbursement headwinds; Compensation Adjusted EBITDA ~ $123M .

Investment Implications

  • Alignment: PRSUs tied to EBITDA and rTSR (60% market condition) increase sensitivity to both execution and relative stock performance; STI zero payout in 2024 underscores performance-contingent pay .
  • Retention risk vs. supply: Chelsey holds no beneficially owned common stock as of the record date but has material unvested RSUs/PRSUs; annual RSU vesting through 2027 and PRSU cliff in 2027 could create periodic selling pressure upon vesting, though anti-hedging/pledging and insider-trading preclearance mitigate misuse of information .
  • Severance economics: Good Reason/without cause provide up to 12 months’ salary and extended healthcare; double-trigger change-in-control with equity acceleration is moderate, balancing retention and shareholder protection; no tax gross-ups .
  • Ownership guideline shortfall: As of year-end 2024, none of the NEOs met ownership guidelines (3x salary for non-CEO); continued accumulation via RSU/PRSU vesting is required, implying time-to-compliance and potential alignment gap near term .